ITGA5 and breast carcinoma: A focus for further work would be to establish if ITGA5-positive breast cancer patients with bone metastases are likely to benefit from volociximab in combination with denosumab, which is the best standard of care for prevention of the skeletal morbidity associated with bone metastases in patients with advanced malignancies [2].